Febuxostat is a xanthine oxidase inhibitor, blocking the enzyme responsible for uric acid production. It helps lower serum uric acid levels, prevent urate crystal formation, and reduce gout flare frequency.
Recommended for:
Patients with chronic gout
Hyperuricaemia when allopurinol is ineffective or contraindicated
Prevention of urate-related complications (including chemotherapy-induced cases)
Gout
Hyperuricaemia in adults, including secondary causes (e.g., during cancer treatment)
Taken orally, with or without food. Initial dose is 40 mg once daily. If uric acid levels remain high, the dose may be increased to 80 mg. Long-term use may be required under regular medical supervision.
Contraindications:
Hypersensitivity to febuxostat
Severe hepatic impairment
Paediatric use
Pregnancy and breastfeeding
Side effects:
Gout flare at treatment initiation
Elevated liver enzymes
Headache
Nausea, diarrhoea
Skin rash, allergic reactions
